Lab result explainedInflammationLast updated November 11, 2026

SPEP and free light chains: what an M-spike, kappa and lambda light chains and the kappa/lambda ratio mean

Serum protein electrophoresis and free light chains (SPEP / sFLC) · Serum protein electrophoresis (SPEP), usually with immunofixation (IFE) and serum free light chains (sFLC); sometimes with 24-hour urine protein electrophoresis (UPEP) · reported in SPEP fractions and M-spike in g/dL (some labs g/L; 1 g/dL = 10 g/L); free light chains in mg/L; ratio has no units

Serum protein electrophoresis (SPEP) is a blood test that separates the proteins in your blood into bands by their electrical charge and size, so the lab can see whether one type of antibody is being overproduced by a single clone of plasma cells. That overproduced antibody shows up as a narrow peak called an M-spike (monoclonal protein, M-protein or paraprotein). The free light chain (sFLC) test measures the two small antibody fragments, kappa and lambda, that float free in the blood; normal kappa is about 3.3 to 19.4 mg/L, lambda 5.7 to 26.3 mg/L, and the kappa/lambda ratio 0.26 to 1.65. Together with immunofixation, which identifies exactly which antibody the spike is made of, these three tests detect about 97 to 99 percent of plasma-cell disorders.

The tests are ordered for unexplained anemia, high calcium, kidney impairment, bone pain or fractures, a high total protein or globulin, a very high ESR, numbness in the feet, recurrent infections or protein in the urine. Most abnormal results are not cancer. The commonest finding is monoclonal gammopathy of undetermined significance (MGUS): a small M-spike under 3 g/dL with no organ damage, present in about 3 percent of people over 50 and 5 percent over 70, which progresses to myeloma or a related disease at roughly 1 percent a year. Myeloma itself requires 10 percent or more plasma cells in the marrow plus evidence of damage, or specific biomarkers such as an involved/uninvolved light-chain ratio of 100 or more.

SPEP also reports the other protein fractions (albumin, alpha-1, alpha-2, beta and gamma globulins), and their pattern carries information of its own: a broad, diffuse rise in gamma globulins (polyclonal) means chronic inflammation, infection, liver disease or autoimmunity rather than a clone; a low gamma band means antibody deficiency; and a low alpha-1 band can be the first clue to alpha-1 antitrypsin deficiency. This page explains how to read each part of the report, what the thresholds are, and how kidney function changes the light-chain ratio.

SPEP / sFLC at a glance

  • What it is: SPEP separates blood proteins into albumin, alpha-1, alpha-2, beta and gamma fractions and detects a monoclonal spike; immunofixation names it (IgG, IgA, IgM, kappa or lambda); free light chains measure unbound kappa and lambda.
  • Normal: no M-spike; gamma globulin about 0.7 to 1.6 g/dL; kappa 3.3–19.4 mg/L; lambda 5.7–26.3 mg/L; kappa/lambda ratio 0.26–1.65 (0.37–3.1 if kidney function is reduced). Labs and assays differ.
  • An M-spike under 3 g/dL with normal blood counts, calcium and kidneys is usually MGUS, which is monitored, not treated; 1 percent a year progress.
  • An M-spike of 3 g/dL or more, or a kappa/lambda ratio of 100 or above with the involved chain over 100 mg/L, points to smoldering or active myeloma and needs hematology referral.
  • A high ratio means excess kappa; a low ratio means excess lambda; both chains raised with a normal ratio is polyclonal and usually reflects kidney disease or inflammation, not a clone.
  • Next step for any new M-spike: CBC, calcium, creatinine, immunoglobulin levels, free light chains, 24-hour urine protein electrophoresis and, depending on size and risk, imaging and a bone marrow biopsy.

Have your whole report? Paste it into the free Lab Explainer

Every marker explained in plain language, in context with the others, with questions to bring to your appointment. No account needed.

What SPEP / sFLC measures

In SPEP, a drop of serum is placed on a gel or in a capillary and an electric current is applied. Proteins migrate at different speeds and settle into five zones: albumin (the largest band, 3.5 to 5.0 g/dL), alpha-1 (alpha-1 antitrypsin; 0.1 to 0.3 g/dL), alpha-2 (haptoglobin, alpha-2 macroglobulin, ceruloplasmin; 0.6 to 1.0 g/dL), beta (transferrin, complement, some IgA; 0.7 to 1.2 g/dL) and gamma (mostly IgG, with IgA and IgM; 0.7 to 1.6 g/dL). Normal antibodies come from thousands of different plasma-cell clones and spread across the gamma zone as a broad hump. When a single clone expands, its identical antibody molecules pile up at one spot and form a sharp, narrow peak: the M-spike, quantified in g/dL by measuring the area under it.

Immunofixation (IFE) runs the same separation and then overlays antibodies against IgG, IgA, IgM, kappa and lambda to identify what the spike is made of, for example IgG kappa. IFE is about ten times more sensitive than SPEP, picking up monoclonal proteins as small as 0.02 g/dL, but it does not measure the amount. Each antibody is built from two heavy chains and two light chains, and plasma cells always make a slight excess of light chains, which circulate free. In a healthy person free kappa and free lambda are produced in a roughly 2:1 ratio and cleared by the kidneys, so their blood ratio sits between 0.26 and 1.65. A clone that makes only kappa or only lambda tips the ratio, which is why the sFLC test detects light-chain myeloma, AL amyloidosis and non-secretory myeloma that SPEP misses.

Kidney function matters because the kidneys clear free light chains. As the filtration rate falls, both chains rise, kappa somewhat more than lambda, and the ratio drifts upward; a renal reference range of 0.37 to 3.1 is used when eGFR is below about 60. Different manufacturers' assays give different absolute values, so a result should be compared only with the range printed on the same report, and trends should be followed on the same assay. Fasting is not required. Recent infection, vaccination or an autoimmune flare can raise both chains and the polyclonal gamma fraction for several weeks.

Normal range for SPEP / sFLC

Reference ranges vary between labs and by age, sex and pregnancy. Use the range printed on your own report.

GroupTypical range (SPEP fractions and M-spike in g/dL (some labs g/L; 1 g/dL = 10 g/L); free light chains in mg/L; ratio has no units)Notes
Albumin fraction3.5–5.0 g/dLFalls with inflammation, liver disease, nephrotic syndrome and malnutrition. Labs differ.
Alpha-1 globulin0.1–0.3 g/dLRises in acute inflammation; a flat or absent band suggests alpha-1 antitrypsin deficiency.
Alpha-2 globulin0.6–1.0 g/dLRises in inflammation and markedly in nephrotic syndrome; falls with hemolysis (haptoglobin consumed).
Beta globulin0.7–1.2 g/dLRises with iron deficiency (transferrin) and high LDL; IgA and some IgM spikes land here. Beta-gamma bridging suggests cirrhosis.
Gamma globulin0.7–1.6 g/dLBroad rise = polyclonal (infection, liver disease, autoimmunity, HIV). Narrow peak = M-spike. Below about 0.6 g/dL = hypogammaglobulinemia.
M-spikeNone detectedAny spike is abnormal and is quantified. Under 3 g/dL without organ damage = MGUS; 3 g/dL or more = smoldering or active myeloma until proven otherwise.
Free kappa light chain3.3–19.4 mg/LFreelite assay (Katzmann 2002); other assays range about 6.7–22.4 mg/L.
Free lambda light chain5.7–26.3 mg/LOther assays about 8.3–27.0 mg/L. Use the range on your report.
Kappa/lambda ratio0.26–1.65 (0.37–3.1 with eGFR under 60)Above 1.65 = kappa clone or reduced kidney clearance; below 0.26 = lambda clone. A ratio of 100 or more, or 0.01 or less, with the involved chain over 100 mg/L is a myeloma-defining event.

Abnormal SPEP or free light chains (M-spike, raised light chains or abnormal ratio)

An M-spike means a single clone of plasma cells (or, for IgM, lymphoplasmacytic cells) is producing one antibody in excess. The size of the spike, the type of antibody, the light-chain ratio and whether there is any organ damage sort the finding into categories. MGUS is an M-spike under 3 g/dL, fewer than 10 percent plasma cells in the marrow, and no related anemia, high calcium, kidney damage or bone lesions (the CRAB features). It needs no treatment, only monitoring. Smoldering myeloma is an M-spike of 3 g/dL or more and/or 10 to 59 percent marrow plasma cells, still without organ damage; it progresses at about 10 percent a year for the first five years. Active myeloma is 10 percent or more marrow plasma cells plus a CRAB feature or one of three biomarkers: 60 percent or more marrow plasma cells, an involved/uninvolved light-chain ratio of 100 or more with the involved chain at least 100 mg/L, or more than one focal lesion on MRI.

The Mayo Clinic risk model for MGUS uses three findings: an M-spike of 1.5 g/dL or more, a non-IgG type (IgA or IgM), and an abnormal free light chain ratio. With none of these, the 20-year risk of progression is about 5 percent; with all three it is about 58 percent. Low-risk MGUS is rechecked at six months and then every two to three years if stable; higher-risk MGUS is checked yearly. An IgM spike raises the different possibility of Waldenström macroglobulinemia or lymphoma. A light chain only abnormality (abnormal ratio with no heavy-chain spike) is light-chain MGUS, which progresses at about 0.3 percent a year, or, when the involved chain is very high, light-chain myeloma.

An abnormal kappa/lambda ratio without an M-spike has three main explanations. If one chain is high and the other normal or low, a small clone is likely and immunofixation plus urine electrophoresis follows. If both chains are high and the ratio is normal or only mildly skewed toward kappa, the cause is reduced kidney clearance or polyclonal overproduction from inflammation, infection or autoimmune disease, not a clone. A ratio far outside the range (for example 8 or 0.05) is almost always clonal. A broad polyclonal rise in gamma globulins on SPEP, with no spike, points to chronic liver disease, chronic infection (including HIV and hepatitis C), rheumatoid arthritis, lupus, Sjögren's syndrome or sarcoidosis rather than a plasma-cell disorder. Raised free light chains with an abnormal ratio can also be the first sign of AL amyloidosis, in which the light chains deposit in the heart, kidneys and nerves; a difference between involved and uninvolved chains above 50 mg/L in someone with unexplained heart failure, heavy proteinuria or neuropathy prompts testing for it.

Common causes

  1. Monoclonal gammopathy of undetermined significance (MGUS)

    The most common cause of an M-spike, found in about 3 percent of people over 50, 5 percent over 70 and more often in Black Americans and in people with an affected relative. The spike is under 3 g/dL, marrow plasma cells are under 10 percent and there is no organ damage. About 1 percent a year progress to myeloma, Waldenström or amyloidosis.

  2. Smoldering (asymptomatic) multiple myeloma

    An M-spike of 3 g/dL or more or 10 to 59 percent marrow plasma cells without CRAB features or myeloma-defining biomarkers. Risk of progression is about 10 percent a year for five years, then falls; high-risk smoldering disease is sometimes treated in trials.

  3. Multiple myeloma

    A clonal plasma-cell cancer with marrow plasma cells of 10 percent or more plus anemia, calcium above 11 mg/dL, creatinine above 2 mg/dL, lytic bone lesions, or one of the biomarkers (60 percent plasma cells, light-chain ratio 100 or more, more than one MRI lesion). Most are IgG or IgA; about 15 to 20 percent make only light chains and show little or no SPEP spike.

  4. Light-chain myeloma and light-chain MGUS

    The clone makes only kappa or only lambda, so SPEP may be normal while the free light chain ratio is grossly abnormal and the urine contains Bence Jones protein. This is why sFLC is added to SPEP in every screen; sFLC plus SPEP plus IFE detects over 97 percent of clonal disorders.

  5. Waldenström macroglobulinemia and lymphoma

    An IgM M-spike comes from lymphoplasmacytic cells rather than classic plasma cells. Large IgM spikes thicken the blood (hyperviscosity) and cause nosebleeds, blurred vision and headache. IgM MGUS progresses to Waldenström or lymphoma at about 1.5 percent a year.

  6. AL (light chain) amyloidosis

    A small clone produces misfolded light chains (lambda in about 70 percent) that deposit in heart, kidneys, nerves, gut and tongue. The M-spike is often small or absent; the sFLC ratio is abnormal in about 90 percent. Suspected with unexplained heart failure with thick ventricular walls, nephrotic-range proteinuria, peripheral or autonomic neuropathy, or an enlarged tongue.

  7. Reduced kidney function

    Free light chains are cleared by the kidney, so as eGFR falls both chains rise and the ratio drifts up toward 2 or 3 even without a clone. A renal reference ratio of 0.37 to 3.1 is applied; a ratio within it with both chains raised in proportion is not clonal.

  8. Polyclonal gammopathy from infection, liver disease or autoimmunity

    Chronic hepatitis, cirrhosis, HIV, tuberculosis, endocarditis, rheumatoid arthritis, lupus, Sjögren's syndrome and sarcoidosis all raise the whole gamma fraction, often to 2 to 4 g/dL, as a broad hump rather than a spike, with both light chains raised and a normal ratio.

  9. Transient or secondary monoclonal bands

    Small, often temporary M-spikes appear after infections, after stem-cell or organ transplantation, with some autoimmune diseases, in chronic lymphocytic leukemia and with certain drugs. Therapeutic monoclonal antibodies (daratumumab, rituximab, and others) can themselves appear as a tiny IgG kappa band on SPEP and IFE.

  10. Other plasma-cell and related disorders

    Solitary plasmacytoma, POEMS syndrome (lambda spike with neuropathy and endocrine changes), monoclonal gammopathy of renal significance (small clone damaging the kidney), cryoglobulinemia and heavy-chain disease are less common causes identified by the pattern plus the clinical picture.

Symptoms that can go with it

  • Often none; MGUS is usually found on tests done for another reason
  • Fatigue, breathlessness or pallor from anemia
  • Bone pain, especially in the back or ribs, or a fracture after minor stress
  • Excessive thirst, constipation, confusion or nausea from high calcium
  • Foamy urine, swollen legs or reduced urine output from kidney involvement
  • Repeated infections, particularly chest and sinus infections, because normal antibodies are suppressed
  • Numbness, tingling or burning in the feet (peripheral neuropathy), seen with MGUS, amyloidosis and POEMS
  • Nosebleeds, blurred vision or headache with a large IgM spike (hyperviscosity)

Low gamma globulins or low protein fractions on SPEP

A low gamma globulin band, below roughly 0.6 g/dL, is called hypogammaglobulinemia and means you are making or keeping too few antibodies. It is confirmed by measuring IgG, IgA and IgM individually; IgG below about 600 mg/dL is the usual cutoff for concern and below 400 mg/dL is severe. In adults the commonest causes are medications (long-term corticosteroids, rituximab and other B-cell therapies, some anti-seizure drugs), loss of protein through the kidney or gut, and blood cancers such as chronic lymphocytic leukemia and myeloma, which crowd out normal plasma cells so that a patient can have a big M-spike and low normal immunoglobulins at the same time. Common variable immunodeficiency, the main primary antibody deficiency diagnosed in adults, typically presents between 20 and 40 with recurrent sinus and chest infections.

Free light chains are rarely reported as low; values below the range for both chains usually mean suppressed antibody production and carry the same meaning as low gamma globulins. A single low chain alongside a high partner chain is read as a clone, not as a deficiency: in myeloma the uninvolved chain is often suppressed below normal, and recovery of the uninvolved chain is one marker of response to treatment. A low albumin band reflects inflammation, liver disease, nephrotic syndrome or malnutrition, and a low or absent alpha-1 band in someone with early emphysema or unexplained liver disease is a reason to measure alpha-1 antitrypsin directly.

Common causes

  1. Immunosuppressive and other medications

    Corticosteroids, rituximab and other anti-CD20 antibodies, mycophenolate, methotrexate, chemotherapy, and some anti-seizure drugs (phenytoin, carbamazepine) reduce antibody production. Rituximab-related hypogammaglobulinemia can last years.

  2. Multiple myeloma and chronic lymphocytic leukemia

    The malignant clone suppresses normal plasma cells, so the uninvolved immunoglobulins (and the uninvolved light chain) fall; this immunoparesis is itself a risk factor for progression in MGUS and smoldering myeloma and a reason for recurrent infections.

  3. Protein loss through the kidney or gut

    Nephrotic syndrome loses IgG into the urine (with low albumin and a high alpha-2 band); protein-losing enteropathy from Crohn's disease, celiac disease, intestinal lymphangiectasia or heart failure loses it into the bowel.

  4. Common variable immunodeficiency and other primary antibody deficiencies

    Low IgG with low IgA or IgM and a poor response to vaccines, presenting with recurrent bacterial sinus, ear and chest infections, bronchiectasis, autoimmune cytopenias or granulomas. Diagnosed by an immunologist.

  5. Severe illness, burns and malnutrition

    Critical illness, extensive burns, sepsis and prolonged undernutrition lower albumin and gamma globulins through increased loss and reduced synthesis.

  6. Alpha-1 antitrypsin deficiency (low alpha-1 band)

    A homozygous ZZ genotype produces a flat alpha-1 zone; carriers may be normal on SPEP. It causes early emphysema, especially in smokers, and liver disease; confirmed by alpha-1 antitrypsin level and genotype.

Symptoms that can go with it

  • Recurrent or unusually severe sinus, ear, bronchial or lung infections
  • Chronic cough with sputum (bronchiectasis) or chronic diarrhea with infections such as Giardia
  • Poor response to vaccines or infections despite vaccination
  • Swelling, foamy urine or weight loss when the cause is protein loss
  • Breathlessness in a younger adult or non-smoker with a low alpha-1 band

Read it alongside

  • Total protein and albumin/globulin ratio — a high total protein with a low A/G ratio is often the first clue to an M-spike or a polyclonal rise; a normal total protein does not exclude light-chain disease.
  • IgG, IgA and IgM (quantitative immunoglobulins) — confirm which class is raised and whether the others are suppressed (immunoparesis), a risk factor for progression.
  • Hemoglobin and CBC — anemia is the commonest CRAB feature; a rouleaux comment on the smear suggests a high paraprotein.
  • Calcium and albumin-corrected calcium — above 11 mg/dL is a myeloma-defining feature.
  • Creatinine and eGFR — kidney impairment defines myeloma and also shifts the light-chain ratio, so it is needed to interpret the sFLC.
  • Beta-2 microglobulin and LDH — used with albumin to stage myeloma (ISS and R-ISS) once it is diagnosed.
  • 24-hour urine protein electrophoresis and immunofixation — detects Bence Jones protein; more than 500 mg of monoclonal light chain in 24 hours separates light-chain MGUS from light-chain myeloma.
  • ESR — a very high ESR (over 100 mm/h) with no infection is a classic prompt for SPEP; paraproteins make red cells stack and fall fast.

What usually happens next

  1. A newly detected M-spike leads to immunofixation (to type it), quantitative immunoglobulins, free light chains, CBC, calcium, creatinine and usually a 24-hour urine protein electrophoresis; together these establish whether any CRAB feature is present.
  2. For an M-spike under 1.5 g/dL that is IgG with a normal light-chain ratio and normal blood counts, calcium and kidneys (low-risk MGUS), guidelines allow deferring the bone marrow biopsy and imaging; the tests are repeated at 6 months, then every 2 to 3 years if stable.
  3. For an M-spike of 1.5 g/dL or more, a non-IgG type, an abnormal ratio, or any abnormal CBC, calcium or creatinine, expect hematology referral with a bone marrow biopsy and whole-body low-dose CT or MRI to look for bone lesions.
  4. If the light-chain ratio is abnormal but kidney function is reduced, ask whether the renal reference range (0.37 to 3.1) was applied before concluding a clone is present; a repeat on the same assay in 6 to 12 weeks is often the next step.
  5. If you have unexplained heart failure, heavy proteinuria, neuropathy or an enlarged tongue alongside an abnormal ratio, ask about testing for AL amyloidosis (NT-proBNP, troponin, urine protein, and a fat-pad or organ biopsy with Congo red staining).
  6. Keep copies of each result: MGUS and smoldering myeloma are managed by trend, and a rising M-spike or light chain on the same assay is more informative than any single value.

Diet, lifestyle and natural levers with evidence

What can move SPEP / sFLC once the cause is known. Nothing here replaces finding the cause.

Nothing natural removes an M-spike; what matters is the trend and the context

Strong evidence

No diet, supplement or herb has been shown to make a monoclonal protein disappear or to reliably prevent MGUS progressing. Transient small bands after infections and vaccinations can resolve on their own within weeks, so a borderline result taken during an illness is often repeated when you are well. Avoid testing within 4 to 6 weeks of a significant infection or vaccination if the aim is a baseline, and have serial tests run by the same laboratory because light-chain assays from different manufacturers are not interchangeable.

Healthy weight and metabolic health

Preliminary evidence

In a US Veterans Affairs cohort of 7,878 people with MGUS, those with obesity were about twice as likely to progress to myeloma over a median of 6 years as those of normal weight, and other cohorts link obesity to a higher risk of developing MGUS in the first place. These are observational associations, not trial evidence that losing weight slows progression, but weight, blood pressure, glucose and lipids are worth managing for their own sake in anyone being monitored for years.

Curcumin

Preliminary evidence

A small Australian randomized crossover trial of 4 g a day of curcumin in 36 people with MGUS or smoldering myeloma found a fall in the free light chain ratio and in urinary N-telopeptide (a bone-turnover marker) in a subset of participants, with an open-label 8 g extension showing similar signals. The study was small, the effect was modest and inconsistent, and no trial has shown curcumin changes the rate of progression; it is not a substitute for monitoring.

High-dose curcumin can increase bleeding with anticoagulants, cause gallbladder contraction and, rarely, liver injury; it may interact with chemotherapy. Tell your hematologist before starting it.

Protecting kidney function and staying hydrated

Moderate evidence

Because the kidneys clear free light chains, dehydration, NSAIDs, intravenous contrast and uncontrolled blood pressure or diabetes all raise light-chain levels and can tip a borderline ratio. In people with a known light-chain clone, kidney injury from light chains (cast nephropathy) is the commonest serious complication, and avoiding nephrotoxins and dehydration is standard advice. Hydration does not lower an M-spike, but it keeps the ratio interpretable and protects the kidneys.

People with heart failure or advanced kidney disease should follow their clinician's fluid advice rather than increasing intake on their own.

When to see a clinician promptly

  • Severe back pain with leg weakness, numbness, or loss of bladder or bowel control in anyone with a known M-spike: possible spinal cord compression from a myeloma lesion, which is an emergency.
  • Confusion, extreme thirst, vomiting or drowsiness with a known paraprotein: possible severe hypercalcemia (calcium above 13 to 14 mg/dL), needing same-day treatment.
  • A sudden drop in urine output, or a creatinine that has jumped, in someone with light chains in the blood or urine: light-chain kidney injury is reversible only if treated quickly.
  • Nosebleeds, blurred vision, headache or breathlessness with a large IgM or IgA spike: possible hyperviscosity.
  • A fever over 100.4 F (38 C) or a severe infection in anyone with low immunoglobulins or a plasma-cell disorder, who may not fight bacterial infection normally.
  • New bone pain, an unexplained fracture, worsening anemia or weight loss during MGUS monitoring, which should prompt an earlier repeat rather than waiting for the scheduled check.

Frequently asked questions

What is a normal kappa/lambda ratio?

On the most widely used assay, 0.26 to 1.65 when kidney function is normal, and 0.37 to 3.1 when eGFR is below about 60. Other assays print slightly different ranges, so use the one on your report. A ratio above the range means excess kappa and below it excess lambda. Mild elevations (say 1.7 to 3) with both chains raised and reduced kidney function are usually not clonal; a ratio of 8 or 0.05 almost always is.

Is a small M-spike always cancer?

No. The large majority of small M-spikes are MGUS, a premalignant condition that is monitored but not treated. A spike under 3 g/dL with normal blood counts, calcium and kidney function and no bone lesions is MGUS by definition, and most people with it never develop myeloma; the overall progression rate is about 1 percent a year, and for low-risk MGUS (IgG, under 1.5 g/dL, normal light-chain ratio) the 20-year risk is about 5 percent.

What does an M-spike of 0.5 g/dL mean?

It is a small monoclonal protein, well below the 1.5 g/dL risk threshold and the 3 g/dL myeloma threshold. If the type is IgG, the free light chain ratio is normal and your blood counts, calcium and kidney function are normal, this is low-risk MGUS, usually rechecked at 6 months and then every 2 to 3 years without a bone marrow biopsy. If it is IgA or IgM, or the ratio is abnormal, the risk is higher and yearly checks and sometimes a marrow biopsy are advised.

What is the difference between SPEP, UPEP, immunofixation and free light chains?

SPEP measures how much monoclonal protein is in the blood. Immunofixation identifies what it is (for example IgG kappa) and is more sensitive but not quantitative. Free light chains measure unbound kappa and lambda, picking up clones that make only light chains. UPEP does the same separation on a 24-hour urine collection to detect and quantify Bence Jones protein. The International Myeloma Working Group recommends SPEP plus immunofixation plus free light chains as the screening set; the urine test is added when a clone is found.

Can kidney disease cause an abnormal kappa/lambda ratio?

Yes. Free light chains are cleared by the kidney, so as kidney function falls both chains rise and the ratio drifts upward, often to 2 or 3, because kappa is cleared faster than lambda in health. A renal reference range of 0.37 to 3.1 is applied when eGFR is under 60. Kidney disease does not usually push the ratio below range or above 3 to 4, so results outside those limits still suggest a clone.

What does polyclonal gammopathy mean?

It means the gamma globulin fraction is raised as a broad hump rather than a narrow spike, because many different plasma-cell clones are all producing antibody in response to something. It is a sign of chronic stimulation (liver disease, chronic infection including HIV and hepatitis C, rheumatoid arthritis, lupus, Sjögren's, sarcoidosis) rather than a plasma-cell cancer. The work-up targets those causes; monitoring for myeloma is not needed.

How often should MGUS be checked?

Guidelines suggest repeating SPEP, free light chains, CBC, calcium and creatinine at 6 months after diagnosis to confirm stability. Low-risk MGUS (IgG, under 1.5 g/dL, normal ratio) is then checked every 2 to 3 years or when symptoms arise; intermediate and high-risk MGUS yearly. Any new bone pain, anemia, infection pattern, kidney change or neuropathy should prompt an earlier check.

Do I need to fast for SPEP or free light chains?

No. Neither test is affected by food. Recent infections, vaccinations and autoimmune flares can raise polyclonal immunoglobulins and both light chains for a few weeks, and dehydration concentrates all proteins slightly, so mention these. If you receive a therapeutic antibody such as daratumumab or rituximab, tell the laboratory, because it can appear as a small IgG kappa band.

References

  1. Protein electrophoresis - serum. MedlinePlus Medical Encyclopedia, US National Library of Medicine (2023)
  2. Rajkumar SV, Dimopoulos MA, Palumbo A, et al.. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology (2014)
  3. Dispenzieri A, Kyle R, Merlini G, et al.. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2009)
  4. Katzmann JA, Clark RJ, Abraham RS, et al.. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clinical Chemistry (2002)
  5. Kyle RA, Therneau TM, Rajkumar SV, et al.. Prevalence of monoclonal gammopathy of undetermined significance. New England Journal of Medicine (2006)
  6. Kyle RA, Larson DR, Therneau TM, et al.. Long-term follow-up of monoclonal gammopathy of undetermined significance. New England Journal of Medicine (2018)
  7. Rajkumar SV, Kyle RA, Therneau TM, et al.. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood (2005)
  8. Hutchison CA, Plant T, Drayson M, et al.. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrology (2008)
  9. O'Connell TX, Horita TJ, Kasravi B. Understanding and interpreting serum protein electrophoresis. American Family Physician (2005)
  10. Chang SH, Luo S, Thomas TS, et al.. Obesity and the transformation of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based cohort study. Journal of the National Cancer Institute (2017)
  11. Golombick T, Diamond TH, Manoharan A, Ramakrishna R. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study. American Journal of Hematology (2012)
  12. Multiple myeloma. Merck Manual Professional Version (2024)

Related markers

Related conditions

Evidence guides

Worried about your number?

Ask AskMN what your SPEP / sFLC result could mean in the context of your other results, symptoms and medications. Free, unlimited, no account needed.

Ask about my SPEP / sFLC

This page is educational and is not medical advice or a diagnosis. Lab results have to be interpreted together with your history, symptoms and other results by a clinician who knows you. Do not start or stop a supplement to change a lab value before the cause is known.